NCT05171660View on ClinicalTrials.gov

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Colorectal Cancer Stage IV
Interventions
DRUG

Sintilimab

Sintilimab Injection: 200 mg, i.v., D1, Q3W

DRUG

Bevacizumab

intravenous bevacizumab (7.5 mg/kg, day 1) in each 21-day cycle

DRUG

Oxaliplatin

intravenous oxaliplatin (130 mg/m2, day 1) in each 21-day cycle

DRUG

Capecitabine

oral capecitabine (1 g/m2, days 1-14) in each 21-day cycle

Trial Locations (1)

310009

RECRUITING

Xuefeng Fang, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER